Business
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing
Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patientsData was presented at the European Renal Association (ERA) 2025Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2Upcoming National Principal Investigator and Key Opinion Leader call planned NASHVILLE,
About this update from Insight Molecular Diagnostics Inc.
[{"type":"image","alt":"Insight Molecular Diagnostics Inc.","displaySize":"","headline":null,"caption":"Insight Molecular Diagnostics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a9omE9cBUejfoy9a_jJadQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4","width":300,"height":114}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Data was presented at the European Renal Association (ERA) 2025","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Upcoming National Principal Investigator and Key Opinion Leader call planned","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":488,"olType":false},{"type":"text","content":"NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a head-to-head comparison with another commercially available test kit.","length":272,"tagName":"p"},{"type":"text","content":"The findings indicated equivalent measurements of donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to assess the risk of transplant rejection, between the two platforms studied.","length":195,"tagName":"p"},{"type":"text","content":"This positive data supports iMDx’s top priority of launching its first clinical molecular diagnostic test kit and capturing value in the estimated $1 billion transplant rejection testing market. In 2025 to date, iMDx is executing the key steps typically necessary to transition from product development to commercialization.",...